Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Jacobson Pharma Corporation Limited ( (HK:2633) ).
Jacobson Pharma Corporation Limited announced a connected transaction involving a 2025 License Agreement between its subsidiary Europharm and LCSTH. This agreement allows LCSTH to use a portion of Europharm’s factory from January 2025 to January 2028, with a monthly fee of HK$218,000. The transaction is considered a one-off connected transaction and a continuing connected transaction under the Hong Kong Listing Rules, subject to reporting and announcement requirements but exempt from circular and independent shareholders’ approval. This move is part of Jacobson’s strategic operations to optimize asset utilization and maintain compliance with regulatory requirements.
More about Jacobson Pharma Corporation Limited
Jacobson Pharma Corporation Limited is a pharmaceutical company involved in the development, production, and distribution of generic drugs and over-the-counter healthcare products. The company operates primarily in the Asian market, focusing on providing affordable healthcare solutions.
YTD Price Performance: 21.00%
Average Trading Volume: 3,340,555
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$2.3B
Learn more about 2633 stock on TipRanks’ Stock Analysis page.